<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9693">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05692323</url>
  </required_header>
  <id_info>
    <org_study_id>IIT2021-18-CHANG-PREHAB</org_study_id>
    <nct_id>NCT05692323</nct_id>
  </id_info>
  <brief_title>A Supervised Prehabilitation Program for Patients With Pancreatic Cancer</brief_title>
  <acronym>PREHAB</acronym>
  <official_title>A Supervised Prehabilitation Program for Patients With Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the use of an exercise program in people with&#xD;
      pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Attendance to exercise sessions as well as impacts on healthcare utilization, muscle mass,&#xD;
      quality of life, physical activity, and post-operative outcomes when applicable will be&#xD;
      monitored.&#xD;
&#xD;
      Study participants will participant in a supervised, in-person exercise program 3 times per&#xD;
      week for 6 weeks. Participants will receive a Fitbit to be worn continuously during the study&#xD;
      and complete surveys and exercise tests at specified timepoints (Baseline, Post-Intervention&#xD;
      Evaluation and 3-Month Follow Up).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2023</start_date>
  <completion_date type="Anticipated">April 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PREHAB Program feasibility will be measured by tracking participant attendance at PREHAB sessions. PREHAB will be considered feasible if 50% of participants attend at least 60% of scheduled sessions.</measure>
    <time_frame>From Baseline to 3 Months</time_frame>
    <description>PREHAB session feasibility is defined as at least 50% of participants attending at least 60% of scheduled sessions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PREHAB Program safety will be assessed through the reporting of unanticipated problems from the baseline visit through to the 3 Month visit.</measure>
    <time_frame>From Baseline to 3 Months</time_frame>
    <description>PREHAB program safety will be evaluated by monitoring unanticipated problems involving risk to subjects or others (UPIRSO).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>Supervised Prehabilitation Exercise Program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PREHAB</intervention_name>
    <description>6-week supervised PREHAB program. Each week of the program consists of 3 x 1 hour supervised training sessions made up of moderate intensity aerobic training and resistance training. In addition to the supervised sessions, patients will be instructed to accumulate a total of 150 minutes per week of moderate aerobic training at home which is measured by a wrist worn FitBit device.</description>
    <arm_group_label>Supervised Prehabilitation Exercise Program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pancreatic cancer diagnosis (any stage)&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Independent ambulation and activities of daily living (Discretion of referring/&#xD;
             treating oncologist)&#xD;
&#xD;
          -  Godin-Shephard Leisure-Time Physical Activity Questionnaire score of ≤ 23&#xD;
&#xD;
          -  Physically able to complete functional assessments including 6-minute walk test, hand&#xD;
             grip strength, short performance physical battery and performance metrics&#xD;
&#xD;
          -  Answers no to all questions on PAR-Q OR is cleared to participate by their treating&#xD;
             oncologist&#xD;
&#xD;
          -  Ability to read, write and understand English&#xD;
&#xD;
          -  Written informed consent obtained from subject and ability for subjects to comply with&#xD;
             the requirements of the study&#xD;
&#xD;
        Inclusion criteria for remote monitoring of physical activity (Fitbit) and online Pain&#xD;
        portal only (failure to meet inclusion criterion below should not preclude subjects from&#xD;
        participating in main study):&#xD;
&#xD;
          -  Access to a smart device capable of Fitbit syncing and accessing the online Pain&#xD;
             portal (www.painguide.com)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has undergone or plans to undergo resection surgery prior to projected completion of&#xD;
             PREHAB exercise intervention&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
        Exclusion criteria for remote monitoring component of the study with Fitbit only (failure&#xD;
        to meet exclusion criterion below should not preclude the subject from participating in&#xD;
        main study):&#xD;
&#xD;
          -  Using a pacemaker, implantable cardiac defibrillator, neurostimulator, cochlear&#xD;
             implants (removable hearing aids permitted), or other electronic medical equipment,&#xD;
             unless the PI deems study participation safe.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Chang, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip Chang, DO</last_name>
    <phone>310 467 4498</phone>
    <email>philip.chang@cshs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abrahm Levi</last_name>
      <phone>310-248-8084</phone>
      <email>abrahm.levi@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Arash Asher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Hendifar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gillian Gresham, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alix Sleight Warner, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>January 11, 2023</study_first_submitted>
  <study_first_submitted_qc>January 11, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2023</study_first_posted>
  <last_update_submitted>April 26, 2023</last_update_submitted>
  <last_update_submitted_qc>April 26, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Philip Chang</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Exercise</keyword>
  <keyword>Prehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

